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1. INTRODUCTION
An early and accurate diagnosis and differentiation from potentially benign focal liver 
lesions  is  important  for  the  appropriate  and  successful  treatment  of  patients  with 
malignant liver tumors, because it influences the decisions on the therapeutic options 
such  as  surgical  resection,  liver  transplantation,  transcatheter  arterial 
chemoembolization (TACE), percutaneous ethanol or radiofrequency ablation (8,52,57).
In selected patients with hepatocellular carcinoma (HCC) or liver metastases, improved 
survival  can be achieved with surgical  resection,  and preoperative evaluation of  the 
number, size, and segmental location of lesions is very important (22,45). Computed 
tomography  during  arterial  portography  (CTAP)  is  considered  the  most  sensitive 
preoperative  imaging  modality  for  the  detection  of  liver  lesions,  with  reported 
sensitivities of 81%-93% (21,26,29,50). However, it has potential disadvantages such as 
invasiveness of the procedure and the high rate of false-positive findings due to the 
difficulties to differentiate benign liver lesions (such as adenoma, hemangioma or focal 
nodular hyperplasia), non-tumorous portal vein perfusion defects and small cysts from 
malignant lesions (7,38).
Magnetic resonance imaging (MRI) after bolus injection of extracellular paramagnetic 
gadolinium chelates is a useful and non-invasive technique for the characterization of 
focal  liver lesions to study tumor enhancement  pattern at  dynamic T1-weighted (w) 
MRI.  However,  although  characterization  of  focal  liver  lesions  is  possible  in 
gadolinium-enhanced MRI with sensitivities between 75.3 to 100%, CTAP is considered 
to be superior for tumor detection (15,18, 20,37,47,59). 
Liver-specific contrast agents, such as superparamagnetic iron oxide (SPIO) particles, 
have been developed to increase the potential  of MR imaging for the detection and 
characterization of focal liver lesions (2,3). SPIO particles are taken up by the reticulo-
endothelial system (RES) cells, so called Kupffer cells, of normal liver parenchyma as 
well  as  by  macrophages  of  the  spleen  and  lymph  nodes  and  shorten  T2  and  T2* 
relaxation time by disturbing the local magnetic field in the liver parenchyma, thereby 
resulting in a signal intensity (SI) loss of normal liver parenchyma (16,25,40,54).
Malignant liver tumors do not have a substantial number of RES cells and appear as 
hyperintense  lesions  contrasting  versus  the  hypointense  liver  parenchyma  after 
application of SPIO on T2-w MR imaging. Thereby the detection of focal liver lesions 
can be improved due to the increased tumor-to-liver tissue contrast (1,11,28,36,43). In 
addition, SPIO particles can also be used for the characterization of focal liver lesions 
based on tumor cell composition and function (2,3)
In several articles the reported sensitivities for the detection of focal liver lesions was 
equivalent for SPIO-enhanced MRI and CTAP with the specificity being substantially 
higher for SPIO-enhanced MRI. Therefore, SPIO-enhanced MRI is considered a useful 
method with a high preoperative diagnostic efficacy (4,10,28,46,48). 
In earlier clinical trials the effects of SPIO particles were evaluated almost exclusively 
on  T2-w fast  spin  echo (FSE)  and T2*-w gradient  echo (GRE)  sequences,  whereas 
usually  not  much  attention  was  paid  to  T1-w  GRE  sequences  (1,24,  40,51,54,58). 
However, the effect of SPIO particles on proton relaxation is not confined to T2 and 
T2*. They also influence T1 relaxivity with increased SI on T1-w GRE sequences at low 
concentrations (9,49).
The newly developed SPIO ferucarbotran (ResovistTM, Schering, Germany) has shown 
promising results in terms of safety as well as in terms of detection and characterization 
of focal liver lesions (4,6,40,54). In contrast to other SPIO agents it can be injected 
rapidly as an intravenous bolus and has demonstrated T1 shortening effects in the early 
perfusion phase following rapid bolus injection. Therefore, with ferucarbotran dynamic 
imaging can be performed, although the amount and pattern of enhancement in liver 
vessels  and  focal  liver  lesions  is  not  considered  equivalent  to  gadolinium  chelates 
(34,39, 41,54).
The purposes of our study are 
- first, we wanted to evaluate and compare the efficacy of ferucarbotran-enhanced T2-w 
FSE and T2*-w GRE sequences at 1.5 T for the characterization of  focal liver lesions 
and to find out characteristic findings of each benign and malignant lesions by means of 
quantitative and qualitative analyses. 
- second, we hypothesized that ferucarbotran-enhanced dynamic T1-w GRE MRI may 
contribute  to  improved  characterization  of  focal  liver  lesions  and  that  specific 
enhancement  patterns  for  different  focal  liver  lesions  might  exist;  we,  therefore, 
evaluated the enhancement of liver parenchyma, liver vasculature and different focal 
liver lesions after bolus injection of ferucarbotran in early dynamic MRI with T1-w 2D-
GRE and 3D-GRE sequences.
1.1 Classification of SPIO Agents (56)
SPIO contrast agents include oral (large) SPIO agents, standard SPIO (SSPIO) agents, 
ultrasmall SPIO (USPIO) agents and monocrystalline iron oxide nanoparticle (MION) 
agents. The former three kinds of agents have been approved for clinical application or 
are being clinically tested, under various generic names and trade names (Table 1,2). 
MION agents are still at the experimental study stage.         
Agent Classification Generic name Trade name Developing company
AMI-121 Oral SPIO Ferumoxsil Lumirem Guerbet
Gastromark Advanced Magnetics
OMP Oral SPIO Abdoscan Nycomed
AMI-25 SSPIO Ferumoxide Endorem Guerbet
Feridex IV Berlex Laboratories
SHU 555A SSPIO Ferucarbotran Resovist Schering
AMI-227 USPIO Ferumoxtran Sinerem Guerbet
Combidex Advanced Magnetics
NC100150 USPIO Clariscan Nycomed
Table  1:  The  generic  and  (planned)  trade  names  of  superparamagnetic  iron  oxide  
(SPIO) agents which are approved or in clinical development.
Agent Particle size Target 
organs
Dose Mode of 
administration
AMI-121 300 nm GI lumen 1.5-3.9 mmol-1 l  Fe 400-
600 ml
p.o.
OMP 3.5 µm GI lumen 0.5 g/l 400-600 ml p.o.
AMI-25 80-150 nm Liver/spleen 15 µmol Fe/kg Slow infusion
SHU 
555A
62 nm Liver/spleen 8 µmol Fe/kg Bolus infusion
Perfusion 4-16 µmol Fe/kg Bolus infusion
MRA 10 µmol Fe/kg Bolus infusion
AMI-227 20-40 nm Lymph 
nodes
30-45 µmol Fe/kg Slow infusion
MRA 14-30 µmol Fe/kg Slow infusion
NC10015
0
20 nm Perfusion 7 µmol Fe/kg Bolus infusion
MRA 50-100 µmol Fe/kg Bolus infusion
Table 2 : Properties and applications of superparamagnetic iron oxide (SPIO) agents
Note- GI; Gastrointestinal,   MRA; MR Angiography,   p.o.; per oral
1.1.1 SSPIO Agents for Liver MR Imaging (16,17,33,41,56)
Ferumoxide (AMI-25, EndoremTM by Guerbet and FeridexTM by Berlex Laboratories) is 
coated  with  dextran,  the  iron  oxide  crystal  is  4.8-5.6  nm,  and  the  hydrodynamic 
diameter  is  80-150 nm.  The  T2  and T1 relaxivities  are  98.3  and 23.9  mmol-1 l  s-1 
respectively. Ferumoxide efficiently accumulates in the liver (approximately 80% of the 
injected dose) and spleen (5-10% of injected dose) within minutes of administration; 
blood half-life is 6 min. Peak concentration of iron were found in liver after 2 hours and 
in the spleen after  4 hours.  Iron is  slowly cleared from liver (half-life,  3 days) and 
spleen  (half-life:  4  days).  Ferumoxide  is  usually  not  bolus-injected  because  of 
cardiovascular  side  effects  and  severe  lumbar  pain.  About  3.6%  of  all  subjects 
experienced  some  type  of  lower  back  pain  or  leg  pain  during  the  infusion.  The 
occurrence of these events was higher in cirrhotic patients. However, in most patients, 
these  adverse  reactions  subsided  following a  short  interruption in  the  infusion.  The 
recommended mode of administration is a dose of 15 µmol Fe/kg in 100 ml of glucose 
5%  and  a  biphasic  infusion  (2  ml/min  over  10  min  and  4  ml/min  over  20  min). 
Ferumoxide allows a wide scan window for T2/T2* weighted imaging (0.5~6 hours after 
administration).
Ferucarbotran (SHU 555A, ResovistTM, Schering, Germany) is a SSPIO characterized 
by a carboxydextran rather than dextran coating. The crystal of ferucarbotran is 4.2 nm 
and the hydrodynamic diameter is 62 nm. The carboxydextran coating (27-35 mg/ml 
with an iron-to-carboxydextran ratio of 1:1 [weight-to-weight ratio]) ensures aqueous 
solubility of the microparticles and prevents aggregation. Ferucarbotran is an aqueous 
suspension containing 0.5 mol/l of iron, 40 mg/ml mannitol and 2 mg/ml of lactatic 
acid,  which  is  adjusted  to  a  pH of  6.5  at  37  degree  Celsius.  The  solution  has  an 
osmolarity  of  0.319  osmol/kg  H2O and  a  viscosity  of  1,031  Mpa·sec  at  37  degree 
Celsius. The T1 relaxivity is 25.4 mmol/l -1 s-1 and T2 relaxivy is 151.0 mmol/l -1 s-1. 
Unlike ferumoxide,  ferucarbotran does not  show side effects  after  rapid intravenous 
injection. A dose of 8 µmol Fe/kg is the recommended quantity for liver T2-w imaging 
at retention phase (after the SPIO particles have been trapped by the phagocytes), which 
can be scanned 30 min after administration. Due to its smaller size and thus stronger T1 
relaxation  property,  ferucarbotran  has  also  been  used  for  T1-w  imaging  and  MR 
angiography.  Dynamic  T1-w MR imaging following bolus  infusion of  ferucarbotran 
mimics signal changes caused by gadolinium chelates.
1.2 Review of Gadolinium Chelates-enhanced Liver MR Imaging (2,3,23)
Dynamic imaging after bolus injection of a gadolinium chelates may currently be the 
single most important component of an MR examination of the abdomen in numerous 
circumstances,  particularly  for  the  detection  and  characterization  of  liver  lesions. 
Images are obtained during four phases relative to the injection of the contrast agent: 
precontrast; arterial (pre-sinusoidal); portal venous (sinusoidal); delayed (extracellular) 
phase.
There are two physiologic principles that allow targeting contrast enhancement: the dual 
blood supply of the liver and the hemodynamics of hepatic tumors. The liver is unique 
among abdominal organs in having a dual blood supply, with the portal vein supplying 
75% to 80% of flow and the hepatic arterial supplying the remaining 20% to 25%. Liver 
tumors, however, receive nearly all their blood supply from the hepatic artery. Hepatic 
tumors are divided into hypovascular or hypervascular, relative to the vascularity of the 
liver. Most benign and malignant hepatic masses are relatively hypovascular, and are 
best detected as low SI lesions against a background of a maximally enhanced liver 
achieved during the portal venous dominant phase of hepatic enhancement. Tumors that 
are  considered  hypervascular  receive  a  rich  hepatic  arterial  flow and  enhance  to  a 
similar  degree  as  liver  parenchyma,  and  may not  be  detected  on  the  portal  venous 
dominant phase of enhancement. They are best detected on the arterial dominant phase 
of enhancement.
1.2.1 Extracellular Contrast Agents 
A variety of different gadolinium chelate formulations are used as extracellular contrast 
agents, these are nonspecific substances, enhancing the extracellular fluid spaces. These 
contrast agents are considered essential for standard MR imaging examination of the 
liver,  especially  in  imaging  of  HCC  or  hypervascular  malignant  tumors.  After 
intravenous bolus administration, gadolinium is distributed rapidly from the vascular 
compartment into the extracellular space prior to renal excretion. The usual clinical dose 
of  gadolinium chelates  is  0.1  mmol/kg  body  weight.  Gadolinium has  paramagnetic 
complexes  that  reduce  T1  relaxivity  to  a  much  greater  extent  than  T2  relaxivity, 
resulting in  tissue  signal  intensity  increases  on T1-w images.  In  general,  maximum 
contrast  effect  occurs  at  20  and  60  seconds  (arterial  and  portal  venous  imaging) 
following intravenous contrast administration.
1.2.2  Characteristic  Findings  of  Focal  Liver  Lesions  in  Unenhanced-  and 
Gadolinium Chelates-enhanced MR Imaging
1. Benign Liver Tumors
• Hemangioma:
Hemangioma is the most common benign hepatic neoplasm, occurring 5% to 20% of 
the population. Women are affected more than are men and the lesions are commonly 
found in a subcapsular location in the right lobe of the liver.
On MR images hemangiomas have a characteristic appearance of a 1 cm to 3 cm lesion 
that is extremely bright (“light bulb”) on T2-w images. Lesions larger than 3 cm tend to 
be  less  homogeneously  bright  due  to  internal  fibrous  septa  or  scarring.  The  tumor 
margin  is  well  defined,  and  may be  somewhat  lobulated.  No peritumoral  edema is 
present.
Dynamic MRI with gadolinium chelates administration may display the slow perfusion 
pattern  of  hemangioma  (i.e.,  progressive  centripetal  filling),  allowing  a  differential 
diagnosis between hemangiomas and primary and secondary malignant tumors.
Three  patterns  of  contrast  enhancement  are  observed  in  hepatic  hemangiomas:  (a) 
uniform  enhancement  in  the  arterial  phase;  (b)  peripheral  nodular  enhancement 
progressing centripetally to uniform enhancement; (c) peripheral nodular enhancement 
with  persistent  hypointensity  centrally.  These  patterns  correlate  with  the size  of  the 
lesions: pattern (a) is seen exclusively in small (< 1.5-cm-diameter) lesions whereas 
pattern (c) is typical for large, giant hemangiomas.
• Focal Nodular Hyperplasia (FNH):
FNH accounts for approximately 8% of all primary hepatic tumors and represents the 
second most common benign liver tumor after hemangioma. Most FNHs are seen in 
women in the third to fifth decades of life.
FNH is a well-circumscribed mass, lacking a true capsule, and is characterized by a 
central scar of vascular connective tissue with prominent arterial vessels that extend 
outward, through fibrous septa, to the periphery of the tumor. 
On precontrast MR images, FNH usually appears isointense with respect to normal liver 
parenchyma on T1- and T2-w images. The central scar appears hypointense on T1-w 
images and hyperintense on T2-w images, owing to the presence of connective tissue 
with rich vascularity. 
On dynamic MRI with gadolinium chelates administration, FNH demonstrates peculiar, 
biphasic enhancement. In the early phase, the central scar is unenhanced, whereas the 
parenchymal portion of the lesions does enhance, becoming definitely hyperintense with 
respect to adjacent hepatic parenchyma. After a few minutes, in the delayed phase, the 
parenchymal  portion  of  the  lesion  appears  almost  isointense  with  respect  to  the 
surrounding normal liver, and the uptake of contrast agent by the central scar can be 
observed, particularily in medium- to large- sized lesions. 
• Hepatocellular Adenoma:
Hepatocellular  adenoma  is  an  uncommon  primary  benign  tumor.  The  incidence  of 
adenoma  increased  following  the  introduction  of  oral  contraceptives,  and  oral 
contraceptives and androgen steroid therapy have been identified as definitive causative 
agents.  Hepatocellular  adenoma can also occur  spontaneously or  be  associated with 
underlying  metabolic  disease.  The  diagnosis  of  this  entity  is  clinically  important 
because  it  can  bleed,  causing  life-threatening  hemorrhage,  and  because  it  has  a 
potential, although very rare, for malignant transformation. 
Hepatocellular adenoma is typically a well-circumscribed tumor. The presence of large 
subcapsular arterial vessels accounts for its typical hypervascular nature.
The  rich  intracellular  content  of  glygogen  is  the  main  element  responsible  for  the 
increased signal intensity of hepatocellular adenoma on T1-w images with respect to 
surrounding liver parenchyma. Areas of internal hemorrhage are typically depicted as 
markedly  hyperintense  areas  on  T1-  and  T2-w  images,  owing  to  the  presence  of 
extracellular methemoglobin. 
On  dynamic  contrast-enhanced  MR  images,  hepatocellular  adenoma  shows  early 
enhancement  during  the  arterial  phase,  reflecting  its  hypervascularity,  with  rapid 
washout.
1.2.2.2 Malignant Liver Tumors
• Hepatocellular Carcinoma (HCC):
HCC is a common malignancy throughout the world, with an estimated incidence of up 
to 1,000,000 new cases per year. The highest incidence rates are found in sub-Saharan 
Africa and the Far East. Areas of low incidence include North America and Northern 
Europe,  whereas Mediterranean countries have an intermediate-to-high incidence.  In 
Western countries and in the Far East, most cases occur in patients with liver cirrhosis, 
following hepatitis B or C infection. 
There are three patterns of HCC in the liver: a solitary mass, a dominant mass with 
smaller  satellite  lesions  (i.e.,  multifocal  HCC),  and  diffuse  involvement.  Most 
commonly,  lesions  are  well  circumscribed  with  the  appearance  of  a  well-defined 
“capsule”.
On  MR  images,  the  T1  appearance  of  HCC  ranges  from  hypointense  to  slightly 
hyperintense, depending on fat  content,  copper deposition within the tumor,  and the 
degree of differentiation. Tumor capsule appears as a low-intensity rim on T1-w images. 
On T2-w images, most HCC demonstrate increased signal compared to the surrounding 
liver, although the tumors tend to be inhomogeneous.
HCC is typically nourished by hepatic arterial blood supply. HCC, therefore, typically 
shows a peak contrast uptake in the arterial phase of the dynamic MR examination. 
Portal  vein  thrombosis  induced  by  malignant  tumor  invasion  demonstrates  early 
contrast  uptake  in  the  arterial  phase  like  the  main  tumor,  and  corresponds  to  the 
arteriographic  “threads  and streaks”  sign  (i.e.  serpiginous  or  bundle  of  threads  like 
opacification due to neovascularization of tumor thrombi within the portal vein.).
• Metastases:
Metastatic disease to the liver is approximately 20 times more common than is primary 
hepatic neoplasms. The most common primary tumors to metastasize to the liver are 
colon, breast, lung, pancreas, melanoma and sarcoma.
The most common appearance of metastatic disease in the liver by MR is round focal 
lesions with decreased signal on T1-w images and moderately increased signal on T2-w 
images. Hypervascular metastases are those with an abundant blood supply, typically 
greater  than  that  of  normal  liver.  These  tumors  include  choriocarcinoma,  renal  cell 
carcinoma, thyroid carcinoma, breast carcinoma, melanoma, carcinoid tumor and islet 
cell tumor. In general, these tumors may have hyperintense signal on T2-w images, and 
so potentially could be mistaken for hemangioma or cyst. In addition, most of these 
tumors have an increased tendency to have intratumoral hemorrhage. This results in 
increased  signal  on  T1-w images  as  well  as  T2-w images.  Melanoma,  due  to  T1-
shortening effect of melanin, shows increased signal on unenhanced T1-w image even if 
hemorrhage is not present.
With dynamic scanning contrast enhancement of metastases is usually delayed when 
compared with that of hemangiomas. Moderate peripheral enhancement may be seen 
with variable but rather slow, irregular enhancement of the central portion of the lesions 
in most cases, and little or no enhancement in others. Hypervascular metastases may 
demonstrate  early  arterial  contrast  enhancement,  but  they  do  not  demonstrate  the 
peripheral  puddling  and  tendency  toward  central  filling,  which  is  characteristic  of 
hemangiomas. 
• Cholangiocellular Carcinoma (CCC):
Intrahepatic CCC is a relatively uncommon neoplasm, although it represents 10% of 
primary liver tumors and is the second most common primary liver malignancy after 
HCC.
The MR appearance of CCC is that of a non-capsulated tumor, hypointense on T1-w 
images and hyperintense on T2-w images. Dilatation of the peripheral portion of the 
intrahepatic biliary ducts may be seen. The SI of the tumor is variable according to the 
amount  of  fibrosis,  necrosis,  and  mucinous  material  within  the  tumor.  Central 
hypointensity may be seen on T2-w images, corresponding to central areas of fibrosis.
On  dynamic  contrast-enhanced  MR  studies,  minimal  to  moderate  peripheral 
enhancement is evident followed by progressive filling. Diffuse interstitial enhancement 
within the tumor,  reflecting the large amount  of fibrotic  tissue,  is  typically  seen on 
delayed MR images. 
 
2. PATIENTS, MATERIALS AND METHODS
2.1 Patients
In this retrospective study 216 consecutive patients, referred for clinical reasons, were 
examined with ferucarbotran-enhanced MR imaging of the liver during a 14 months 
period. Of 216 patients, we selected 173 patients with focal liver lesions. All patients 
gave written informed consent for the examination. Since the examination was part of 
the clinical routine work-up, no ethic board approval was needed.
Exclusion criteria for SPIO-enhanced liver MR imaging: 
• Patient age less than 18 years
• Any contraindication to MR imaging
• Acute hepatitis or serious liver dysfunction
• Severe renal failure
• History of severe adverse events related to drugs or contrast agents
• Pregnancy or lactation in women
• Iron overload
• Injection of an investigational drug within 30 days before the study
• Intravenous administration of contrast material within 24 hours before MR imaging
2.1.1 Study I (T2-weighted FSE and T2*-weighted GRE sequences)
Of  173  patients,  105  were  excluded  from  this  study  due  to  missing  confirmative 
diagnosis  (n=51),  lost  imaging  data  (n=2),  severe  artifact  (n=6)  status  after  TACE 
(n=17) and inadequate examination (n=29). The remaining 68 patients with a mean age 
of 61 years (age range, 21-79 years; 19 women, 49 men) were included in this study. 
The distribution of the different lesions in the study population is given in Table 3. 
Diagnosis
Diagnostic Method
*Pathological (n=36) **Follow Up (n=32)
Malignant (n=46)
HCC (n=29)
Metastasis (n=15)
CCC (n=2)
21
8
1
8
7
1
Benign (n=22)
Hemangioma (n=6)
Adenoma (n=5)
FNH (n=3)
Cyst (n=8)
1
3
2
5
2
1
8
Table 3: Case distribution in study group I according to confirmative diagnostic method  
(n=No. of case).
Note- * Pathological confirmation was obtained by fine needle aspiration biopsy (n=25) 
and surgery (n=11). ** The diagnosis was made with clinical and radiological follow-up.
CCC;  Cholangiocellular  Carcinoma,  FNH;  Focal  Nodular  Hyperplasia,  HCC;  
Hepatocellular Carcinoma
2.1.2 Study II (T1-weighted early dynamic GRE sequences)
Of  173  patients,  113  were  excluded  from  this  study  due  to  missing  confirmative 
diagnosis  (n=69),  lost  imaging data  (n=2),  severe artifacts  (n=4),  status  after  TACE 
(n=17) and because the dynamic examination was not performed (n=21). The remaining 
60 patients with a mean age of 61.2 years (age range, 21-79 years; 17 women, 43 men) 
were included in this study.  
The distribution of the different lesions in the study population is given in Table 4. 
Diagnostic Method
Diagnosis *Pathological (n=32) **Follow Up (n=28)
Malignant (n=41)
HCC (n=25) 17 8
Metastasis (n=14) 7 7
CCC (n=2) 1 1
Benign (n=19)
Hemangioma (n=6) 1 5
Adenoma (n=3) 3
FNH (n=3) 3
Cyst (n=7) 7
Table  4:  Case  distribution  in  study  group  II  according  to  confirmative  diagnostic  
method.
Note- *Pathological confirmation was obtained by fine needle aspiration biopsy (n=23)  
and surgery (n=9).** The diagnosis was made with clinical and radiological follow-up.
CCC;  Cholangiocellular  Carcinoma,  FNH;  Focal  Nodular  Hyperplasia,  HCC;  
Hepatocellular Carcinoma
The T1-w dynamic studies were performed with 2D-GRE sequences in 23/60 during the 
first  9  months  and  with  3D-GRE  VIBE  (Volumetric  Interpolated  Breath-hold 
Examination) sequences in 37/60 patients during the following 5 months of the study 
interval. The change from the 2D-GRE to the 3D-GRE sequences was due to a change 
of the sequences in the routine liver MR protocol.
The distribution of the cases according to each sequence is shown in Table 5.
Sequence for dynamic imaging
Diagnosis 2D-GRE (n=23) 3D-GRE VIBE (n=37)
HCC (n=25) 16 9
Metastasis (n=14) 4 10
CCC (n=2) 1 1
Hemangioma (n=6) 2 4
Adenoma (n=3) 3
FNH (n=3) 3
Cyst (n=7) 7
Table 5: Case distribution according to T1-weighted GRE dynamic MRI Sequences
• Diagnostic Criteria with Clinical and Radiological Follow-up:
With clinical and radiological follow-up, diagnosis of liver metastasis was made on the 
basis of surgically proven primary tumor, increased levels of serum tumor marker, and 
tumor  growth  on  follow-up  sonography,  CT  and/or  MR  imaging.  Lesions  were 
diagnosed  as  HCC  if  they  had  underlying  liver  cirrhosis,  showed  typical  imaging 
findings  on  CT,  sonography  and  angiography,  and  increased  levels  of  serum  α-
fetoprotein.  Lesions  were  diagnosed  as  adenoma  if  they  presented  as  hyperintense 
lesions on T1-w MR image, showed strong arterial enhancement with rapid wash out on 
dynamic CT or MRI and no increase in size for 6 months and in the case of patients 
suffering from underlying glycogen storage disease. Lesions were diagnosed as FNH if 
they showed nearly same density or SI as the normal liver parenchyma on CT and MR 
images, presented with a central scar that showed bright SI on T2-w MR images and did 
not exhibit increase in size for 6 months. Lesions were diagnosed as hemangioma if 
they were well-marginated hyperechoic masses at sonography, showed dense peripheral 
nodular enhancement in the arterial phase with subsequent centripetal fill-in on contrast-
enhanced CT or MR images, were markedly hyperintense on prior T2-w MR images 
and showed no increase in size for 6 months. Lesions were diagnosed as cysts if they 
showed HU values of 0-15 and no enhancement on contrast-enhanced CT scans or were 
anechoic with posterior sonic enhancement at sonography.
2.2 Contrast Agent
The  liver-specific  SPIO  ferucarbotran  (ResovistTM,  Schering,  Germany)  was  used. 
Before  each  examination,  an  intravenous  catheter  was  placed  in  an  arm  vein  and 
attached  through  a  connecting  line  to  a  20-ml  syringe  to  prevent  the  patient  from 
changing position during examination. Patients up to 60 kg body weight received 0.9 ml 
ferucarbotran  and patients  above 60  kg  body weight  received 1.4 ml  ferucarbotran. 
Ferucarbotran was administered through a 5 μm filter carefully into the connecting tube 
by hand then injected rapidly as an intravenous bolus by hand together with a 20-ml 
saline flush. 
2.3 MR Imaging Method
MR  imaging  studies  were  performed  at  1.5-T  high  performance  gradient  systems 
(Sonata and Symphony Quantum, Siemens, Erlangen, Germany), using a phased array 
body coil.
2.3.1 Study I (T2-weighted FSE and T2*-weighted GRE sequences)
After non-enhanced (NCE) T2-w FSE images were obtained, contrast-enhanced (CE) 
T2-w FSE images 10 min after bolus injection were obtained, followed by CE- T2*-w 
GRE images. NCE- T2*-GRE images were not obtained
Imaging parameters for T2-w FSE and T2*-GRE sequences are shown in Table 6.
T2-w FSE sequence T2*-w GRE sequence
TR (msec)/TE (msec)/flip angle 2800/125 117/100/30°
Section thickness/gap 6 mm/0.6 6 mm/0.6
Matrix 256×256 256×256
Field of view 300-400 300-400
Fat saturation (+) (-)
Breath hold (+) (+)
Table 6: Parameters for T2-weighted FSE and T2*-weighted GRE sequences
2.3.2 Study II (T1-weighted early dynamic GRE sequences)
Axial T1-w dynamic imaging was obtained before, and 20, 50 and 120 seconds after 
bolus injection of ferucarbotran. 
Imaging parameters for T1-w 2D-GRE and T1-w 3D-GRE VIBE sequences are shown 
in Table 7. 
2D-GRE sequence 3D-GRE sequence
TR (msec)/TE (msec)/flip angle 174/4.76/70° 4.45/1.54/15°
Section thickness/gap 8 mm/0.8 4 mm/0
Matrix 256×256 256×192
Field of view 300-400 300-400
Fat saturation (-) (+)
Breath hold (+) (+)
Table  7:  Parameters  for  T1-weighted  2D-GRE  and  T1-weighted  3D-GRE  VIBE 
sequences
2.4 Quantitative Image Analysis
On a picture archiving and communication system (PACS, Magic View 1000, Erlangen, 
Germany),  one  radiologist  performed  operator-defined  region-of-interest  (ROI) 
measurements.
2.4.1 Study I (T2-weighted FSE and T2*-weighted GRE sequences)
The ROI measurements were performed for the SI of liver parenchyma (in regions free 
of artifacts and of large blood vessels) and focal liver lesions (excluding central necrosis 
or scar) and background noise on NCE- and CE- T2-w FSE and CE-T2*-GRE images.
2.4.2 Study II (T1-weighted early dynamic GRE sequences)
The ROI measurements were performed for the SI of liver parenchyma (in regions free 
of artifacts and large blood vessels), portal vein, aorta, inferior vena cava (IVC) and 
focal liver lesions (excluding central necrosis or scar) and background noise before and 
after injection of the contrast agent. 
• ROI measuring methods:
ROIs were placed in the same anatomic area with the same size and shape on both 
NCE-  and  CE-  images.  For  the  measurement  of  SI  of  liver  tissue  and  aorta,  three 
separate ROIs from different areas were measured, and the results were averaged. For 
the measurement of SI of IVC and portal vein, only one ROI was measured. For the 
hepatic  lesions,  circular  ROIs  were  drawn  to  encompass  as  much  of  the  lesion  as 
possible. If the focal lesion was totally inhomogeneous in SI, two separate ROIs from 
high and low SI areas were measured and the results were averaged. If the lesion was 
inhomogeneous with different SI in the center and the rim, the SI of the rim was chosen, 
since it defines the contrast to the liver parenchyma. If multiple lesions were present in a 
patient,  a single lesion of the largest size and best representing the lesions type was 
chosen and ROIs were measured. If different lesion types were present in a patient, we 
preferred solid malignant lesions to solid benign and cystic lesions. Background noise 
was measured in ROIs as large as possible ventrally to the liver outside the patient along 
the phase-encoding axis, avoiding ghosting artifacts that might have propagated over the 
image. 
• Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR):
Signal Intensity of liver or lesion
Standard Deviation of background noise
Signal Intensity of lesion – Signal Intensity of liver
Standard Deviation of background noise
SNR precontrast – SNR postcontrast × 100
SNR precontrast
SNR  =  
CNR  = 
 • The percentage of signal intensity loss (PSIL) of the lesion in CE-T2-w FSE images:
 PSIL = 
• Statistical Analysis:
In study group I, the statistical significance of the difference in SNR, CNR and PSIL 
between the lesions and between the imaging sequences was evaluated by means of the 
paired t-test. Sensitivity and specificity for the differentiation of benign and malignant 
lesions were calculated with the different threshold PSIL of 20%, 25% and 30%.
In study group II, the change in SNR and CNR between unenhanced and 20 second 
phased images in each organ and lesion was evaluated by means of the paired t-test, and 
difference between different patients groups by means of the unpaired t-test. 
P-values less than or equal to 0.05 were considered statistically significant.
Statistical analysis was performed with SPSS 12.0 (Statistical Package for the Social 
Science; SPSS Inc., Chicago, Illinois).
2.5 Qualitative Analysis
2.5.1 Study I (T2-weighted FSE and T2*-weighted GRE sequences)
On a PACS two radiologists experienced in liver MR imaging visually evaluated the 
two image sequences (CE-T2-w FSE and CE-T2*-w GRE) for each case and made a 
consensus for the following categories:
• Overall image quality
• Lesion conspicuity
• Vessel conspicuity
• Imaging artifacts
• Detected lesion number
• Additional findings (which may be useful in characterization of focal liver lesions); 
portal vein thrombosis, mosaic pattern in the tumor, tumor capsule, central scar, high SI 
rim outside the tumor
The criteria for the assessment of overall image quality were visual quality of the liver 
margin,  depiction  of  the  vascular  structures,  and  homogeneity  of  the  SI  in  liver 
parenchyma and presence of image artifacts. 
• Statistical Analysis
The two image sequences were compared for each category and scored as follows: CE-
T2-w FSE superior, CE-T2*-w GRE superior, equal, or not identified. In each category, 
the cases scored as “equally” or “not  identified” were discarded,  and the remaining 
cases were tested for statistical significance by means of Chi-square and Fischer exact 
tests. The results were considered significant at p < .05.
2.5.2 Study II (T1-weighted early dynamic GRE sequences)
Two radiologists visually evaluated the dynamic enhancement pattern of the different 
lesions over time and made a consensus to find out whether characteristic enhancement 
pattern  existed  that  might  be  equivalent  to  known  enhancement  pattern  from 
gadolinium-enhanced dynamic MRI. Hypo- or hyperintensity was defined as lower or 
higher SI of the lesion in comparison to the adjacent liver parenchyma.
3. RESULTS
3.1 Study I (T2-weighted FSE and T2*-weighted GRE sequences)
3.1.1 Quantitative Analysis
• SNR and CNR:
The mean SNR of the liver and focal lesions on each imaging sequence are shown in 
Graph 1. 
21,2
26,4
24,4
45,3
47,0 47,7
43,3
39,3
27,2
30,6
27,6
11,2
14,0
16,3
29,2 30,7
0,0
10,0
20,0
30,0
40,0
50,0
60,0
Liver Adenom a FNH Hemang. Cyst HCC CCC Met a.
SNR
T 2-pre T 2-post
Graph 1. SNR of the liver and focal liver lesions at pre- and post- contrast enhanced  
T2-weighted FSE and post-contrast enhanced T2*-weighted GRE images.
Note- CCC; Cholangiocellular Carcinoma, FNH; Focal Nodular Hyperplasia, HCC;  
Hepatocellular Carcinoma
The SNR of the liver significantly decreased from 21.2 on NCE-T2-w FSE images as 
compared with 11.2 on CE-images (p< .05).  The mean SNR of solid benign lesions 
showed a decrease from 34.1 to 21.0 (p< .05). In malignant lesions, the mean SNR 
showed only a minor decrease from 33.3 to 32.5 (n.s.). 
The statistical significance in the difference of SNR between the lesion types on each 
imaging sequence is shown in Table 8. 
Adenoma 
vs 
FNH
Hemangioma 
vs 
HCC
Hemangioma 
vs 
Metastasis
Cyst 
vs 
HCC
Cyst 
vs 
Metastasis
HCC 
vs 
Metastasis
NCE-T2-
w FSE
NS < .05 NS < .05 NS NS
CE-T2-w 
FSE
NS NS < .05 NS NS < .05
CE-T2*-
w GRE
< .05 NS NS < .05 < .05 NS
Table 8. Statistical significance of the difference in SNR between the lesion types (p-
value).
Note.- < .05: statistically significant ; NS: statistically not significant
CCC;  Cholangiocellular  Carcinoma,  FNH;  Focal  Nodular  Hyperplasia,  HCC;  
Hepatocellular Carcinoma
The mean CNR of focal lesions in comparison to the adjacent liver parenchyma on each 
imaging sequence is shown in Graph 2. The mean CNR of the malignant lesions was the 
highest in the CE-T2*-w sequence as compared to the CE- and the NCE- T2-w FSE 
sequence (29.9 vs. 22.7 (p< .01) vs. 12.8 SI (p< .01)). The mean CNR of adenoma and 
cyst were statistically significantly lower than those on CE-T2-w FSE images (p < .05). 
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Graph 2. CNR of focal liver lesions at pre- and post- contrast enhanced T2-weighted  
FSE and post-contrast enhanced T2*-weighted GRE images.
Note- CCC; Cholangiocellular Carcinoma, FNH; Focal Nodular Hyperplasia, HCC;  
Hepatocellular Carcinoma
The statistical significance in the difference of CNR between the lesion types on each 
imaging sequence is shown in Table 9.
Adenoma 
vs
 FNH
Hemangioma 
vs 
HCC
Hemangioma 
vs 
Metastasis
Cyst 
vs 
HCC
Cyst 
vs 
Metastasis
HCC 
vs 
Metastasis
NCE-T2-
w FSE
NS < .05 < .05 < .05 < .05 NS
CE-T2-w 
FSE
NS NS NS < .05 NS NS
CE-T2*-
w GRE
< .05 NS NS < .05 < .05 NS
Table 9. Statistical significance of the difference in CNR between the lesion types (p-
value).
Note- < .05: statistically significant; NS: statistically not significant
CCC; Cholangiocellular Carcinoma, FNH; Focal Nodular Hyperplasia, HCC; 
Hepatocellular Carcinoma
• PSIL:
The  mean  PSIL (90%  Confidence  Intervals)  of  each  lesion  type  were  as  follows: 
Adenoma 46.9% (38.8% to 55.0%), FNH 33.0% (21.3% to 44.7%), hemangioma 35.3% 
(26.9% to 43.8%), HCC 3.1% (–1.4% to 7.6%), Metastasis 4.0% (–1.4% to 9.5%), CCC 
–1.7% (–22.3% to 18.8%). The PSIL of non-cystic benign lesions (mean PSIL 39.6%)
were statistically significantly higher as compared to that of malignant lesions (mean 
PSIL 3.2%). The distribution of PSIL of each focal liver lesion (14 non-cystic benign 
and 46 malignant lesions) is shown in Graph 3. 
PSIL in %
Graph 3. Percentage of signal intensity loss (PSIL) in noncystic benign (n=14) and 
malignant  lesions  (n=46)  on  T2-weighted  FSE  sequences  after  ferucarbotran  
administration...................................................................................................................  
Note-  CCC; Cholangiocellular Carcinoma, FNH; Focal Nodular Hyperplasia, HCC;  
Hepatocellular Carcinoma
When the threshold PSIL for the differentiation of benign and malignant lesions was 
determined at 25%, 45 of 46 malignant lesions and one of 14 benign lesions showed a 
PSIL lower than 25%, resulting in a sensitivity and specificity for the characterization of 
malignant lesions of 97.8% and 92.9%. The malignant lesion with a PSIL higher than 
25% was a HCC (PSIL 28.1%), and the benign lesion with a PSIL lower than 25% was 
a hemangioma (PSIL 19.5%). 
When the threshold was determined at 30%, 46 of 46 malignant lesions and 3 of 14 
benign lesions showed a PSIL lower than 30%, resulting in a sensitivity and specificity 
for the characterization of malignant lesions of 100% and 78.6%. When the threshold 
was determined at 20%, 44 of 46 malignant lesions and 1 of 14 benign lesions showed a 
PSIL lower than 20%, resulting in a sensitivity and specificity for the characterization of 
malignant lesions of 95.7% and 92.9%
3.1.2 Qualitative Analysis
The results of visual comparison of two image sequences (CE-T2-w FSE and CE-T2*-w 
GRE) are shown in Table 10. CE-T2*-w GRE images were superior to CE-T2-w FSE 
images with statistical  significance in the categories of overall  image quality,  lesion 
conspicuity and vessel conspicuity (p < .05). Imaging artifacts were more frequently 
shown  on  the  CE-T2-w  FSE  images  than  CE-T2*-w  GRE  images  with  statistical 
significance (p < .05). In the categories of additional findings no significant difference 
between the two sequences was noted (p > .05).
Category T2-w FSE
superior
T2*-w GRE
superior
Equally
rated
N p-value
Overall Image Quality 7 44 17 NA < .05
Lesion Conspicuity a16 40 12 NA < .05
Vessel Conspicuity 1 49 18 NA < .05
Artifact 28 7 6 27 < .05
Detected Lesion Number c7 11 14 b35 NS
Additional Findings
Portal Vein Thrombosis 2 1 4 61 NS
Mosaic Pattern 5 1 1 61 NS
Capsule 2 3 1 62 NS
Central Scar 1 0 1 66 NS
Peripheral rim 1 5 0 62 NS
Table 10. Comparison of image scores for contrast-enhanced T2-weighted FSE versus 
T2*-weighted GRE sequences
Note- Numbers in the T2-w FSE and T2*-w GRE columns indicate the number of cases 
in which each of the sequences was rated superior. Equally rated = numbers of cases 
for which the T2-w FSE and T2*-w GRE sequences were rated equal, N = number of  
cases in which a finding was not identified with either sequences, NA = not applicable,  
NS = not significant.
a Eight of them were cyst.
b Five of them had too numerous focal lesions to count.
c Six of them were benign lesions (one FNH, 3 cyst, 2 Hemangioma).
• Lesion Conspicuity (Table 11):
In general, overall image quality and imaging artifacts affected the lesion conspicuity 
(Figure 2). The superiority of lesion conspicuity on CE-T2*-w GRE images was caused 
by markedly negative (adenoma) or positive (HCC) CNR in adenoma and HCC. In 
cysts the CNR on CE-T2*-w GRE images was markedly decreased in contrast to the 
bright  signal  intensity  on  CE-T2-w  FSE  images  resulting  in  inferiority  of  lesion 
conspicuity.
T2-w FSE
superior
T2*-w GRE
superior
Equally
rated
Adenoma (n=5) 0 5 0
FNH (n=3) 1 2 0
Hemangioma (n=6) 3 3 0
Cyst (n=8) 8 0 0
HCC (n=29) 1 24 4
Metastasis (n=15) 1 10 4
CCC (n=2) 0 1 1
Table 11. Lesion conspicuity according to the lesion types.
Note- Numbers in the T2-w FSE and T2*-w GRE columns indicate the number of cases 
in which each of the sequences was rated superior. Equally rated = numbers of cases 
for which the T2-w FSE and T2*-w GRE sequences were rated equal.
CCC; Cholangiocellular Carcinoma, FNH; Focal Nodular Hyperplasia, HCC; 
Hepatocellular Carcinoma
• Imaging Artifacts:
The imaging artifacts found on CE-T2-w FSE images were motion artifacts in 33 of 68 
cases (48.5%) and ghosting artifacts from the GB in one case.  In eight patients  the 
artifacts were severe enough to degrade the image quality with blurring of liver and 
lesion margins; in those eight patients seven suffered from a large amount of ascites 
(Figure  1).  The  imaging  artifacts  arising  on  CE-T2*-w  GRE images  were  ghosting 
artifacts in 8 of 68 cases (11.8%), seven from the aorta and one from the IVC, metallic 
artifacts in 3 cases, and motion artifacts and other type in each one. In each one case the 
ghosting artifacts arising from the aorta and the metallic artifacts obscured a focal liver 
lesion  directly  (Figure  2).  In  4  cases  the  ghosting  artifacts  from  the  aorta  were 
mimicking a focal lesion in left hepatic lobe. The metallic artifacts (n=3) were arising 
from the anterior abdominal wall, from surgical clips at the margin of right hepatic lobe 
after liver resection and from surgical material in the vertebral column in each one case. 
Although these artifacts were also shown on CE-T2-w FSE images, they did not affect 
significantly the image quality or lesion conspicuity on CE-T2-w FSE.
• Adenoma:
All adenomas (n=5) showed very dark SI on CE-T2*-w GRE images being hypointense 
to the surrounding liver parenchyma. Two cases showed isointense SI with central foci 
of  high  SI  mimicking  FNH  on  CE-T2-w  FSE  images.  These  lesions  could  be 
differentiated from FHN due to very dark SI of the lesions on CE-T2*-w GRE images 
(Figure 3).
Three patients had multiple adenomas. In two patients, the number of detected lesions 
were higher on CE-T2*-w GRE images rather than CE-T2-w FSE due to the marked 
negative CNR on CE-T2*-w GRE images. One case excluded due to too numerous focal 
lesions to count.
• FNH:
FNH were slightly hyper- or iso- intense on CE-T2-w FSE and CE-T2*-w GRE images. 
Two cases had a central scar. One case showed the central scar on CE-T2-w FSE image 
only, but not on CE-T2*-w GRE image (Figure 4). Another case of FNH showed the 
central scar on both image sequences, although it presented higher SI on the CE-T2-w 
FSE image.
• Hemangioma:
Hemangioma presented in five of six cases with high SI on CE-T2-w FSE and CE-T2*-
w  GRE  images  with  no  visually  noticeable  change  in  SI  after  ferucarbotran 
administration. One hemangioma exhibited a visually noticeable signal decrease in the 
ferucarbotran-enhanced images.
A case of hemangioma combined multiple simple cysts. Both lesion types presented 
with bright SI on NCE-T2-w FSE images. Hemangioma showed signal decrease on both 
CE-T2-w FSE and CE-T2*-w GRE images as compared to NCE- T2-w FSE images. In 
contrast, cyst presented with bright SI on CE- T2-w FSE as well as NCE-T2-w FSE 
images  and worsened lesion  conspicuity  due  to  decreased CNR on CE-T2*-w GRE 
images.
• HCC and Metastases:
HCC showed variable SI on NCE- and CE- T2-w FSE images and high SI with highest 
CNR on CE- T2*-w GRE images (Figure 5). Metastases showed high SI with or without 
an internal heterogeneous area on both sequences (Figure 6). In each one patient HCC 
and metastasis presented combined with simple cysts. In these cases, the differentiation 
between the malignant lesion and the cyst was easier on CE-T2*-w GRE images rather 
than CE-T2-w FSE images due to the marked difference of SI and CNR between the 
two lesion types. 
The results of the visual evaluation of the morphological features, such as portal vein 
thrombosis, central scar, mosaic pattern and dark SI capsule, which may be useful for 
the characterization of focal lesions, are shown in Table 10. These findings showed no 
statistically significant difference between two image sequences. Mosaic pattern only 
showed the tendency toward a better visualization on CE-T2-w FSE images (p > .05) 
(Figure 5). A peripheral hyperintense rim outside the tumor could be delineated in 3 of 
29 cases of HCC and 3 of 25 cases of metastases. In the assessment of this finding CE-
T2*-w GRE images were superior in five cases (n.s.) (Figure 6). In twenty-three patients 
multiple malignant liver lesions were present. In eight of these cases more focal lesions 
were detected on CE-T2*-w GRE images. In one case, more focal lesions were detected 
on CE-T2-w FSE images. Ten cases showed the same number of detected lesions on 
both image sequences. Four cases were excluded due to too numerous focal lesions to 
count. 
3.2 Study II (T1-weighted early dynamic GRE sequences)
3.2.1 Quantitative Analysis
3.2.1.1 T1-weighted 2D-GRE Dynamic MR Image
• SNR and CNR Change in Liver and Vascular Structures:
In the evaluation of liver and vessel SI all vascular structures (IVC and portal vein) 
showed a negative CNR to the liver parenchyma until 50 seconds after contrast injection 
(i.e. the vascular structures were hypointense to the liver) (Graph 4).
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Graph 4. Change in mean CNR of the vascular structures on dynamic T1-weighted 2D-
GRE MRI (n=23) after bolus-injection of ferucarbotran.
Note- IVC; Inferior Vena Cava 
• SNR and CNR Change in Focal Liver Lesions (Graph 5, 6):
In the group of benign lesions hemangioma (n=2) showed a negative CNR after 20 and 
50 seconds and a positive CNR (8.9 ± 26.1) after 120 seconds.
In the evaluation of malignant lesions the SNR in HCC and metastasis increased rapidly 
20 seconds after injection. The early increase in SNR was statistically significant (p < 
.05). Nevertheless, HCC, metastasis and CCC showed a negative mean CNR at all time 
points. 
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Graph 5. Change in mean SNR of focal liver lesions on dynamic T1-weighted 2D-GRE 
MRI (n=23).
Note- CCC; Cholangiocellular Carcinoma, HCC; Hepatocellular Carcinoma
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Graph 6. Change in mean CNR of focal liver lesions on dynamic T1-weighted 2D-GRE 
MRI (n=23).
Note- CCC; Cholangiocellular Carcinoma, HCC; Hepatocellular Carcinoma
3.2.1.2 T1-weighted 3D-GRE Dynamic MR Image
• SNR and CNR Change in Liver and Vascular Structures:
In the evaluation of liver and vessel SI all vascular structures (aorta, IVC and portal 
vein)  had statistically  significantly  increased CNR to the liver  parenchyma after  20 
seconds (p < .05) in comparison to precontrast, and showed positive values at all time 
points after injection (i.e. the vascular structures were hyperintense to the liver) except 
for IVC after 20 seconds (-2.2 ± 20.1) (Graph 7). 
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Graph 7. Change in mean CNR of the vascular structures on dynamic T1-weighted 3D-
GRE VIBE MRI (n=37)
Note- IVC; Inferior Vena Cava
• SNR and CNR Change in Focal Liver Lesions (Graph 8, 9) :
For benign lesions the SNR and accordingly the CNR were highest in adenomas and 
lowest in cysts at all time points. In hemangioma the CNR changed from negative (-7.6 
± 18.0) at precontrast to positive (9.1 ± 35.4) at 20 seconds after injection and then 
persisted positive on subsequent phases. The CNR in FNH remained unchanged with a 
value of more or less zero at all time points (-2.0 ± 6.2; 2.6 ± 24.6; 0.8 ± 22.9; 2.5 ± 
17.2). 
The SNR and CNR in malignant solid lesions (HCC, metastases and CCC) was below 
those of benign noncystic lesions (adenoma, FNH, hemangioma) at all time points after 
injection,  but this difference was not statistically significant (p > .05).  The CNR of 
malignant solid lesions was negative at all time points; however it was higher than that 
of cysts. 
The change in CNR in all benign and malignant lesions after 20 seconds in comparison 
to precontrast was statistically not significant (p > .05).
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Graph 8. Change in mean SNR of focal liver lesions on dynamic T1-weighted 3D-GRE 
VIBE MRI (n=37).
Note- CCC; Cholangiocellular Carcinoma, FNH; Focal Nodular Hyperploasia, HCC;  
Hepatocellular Carcinoma
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Graph 9. Change in mean CNR of focal liver lesions on dynamic T1-weighted 3D-GRE 
VIBE MRI (n=37).
Note- CCC; Cholangiocellular Carcinoma, FNH; Focal Nodular Hyperploasia, HCC;  
Hepatocellular Carcinoma
3.2.2 Visual Evaluation
3.2.2.1 T1-weighted 2D-GRE Dynamic MR Image
• Hemangioma:
Hemangioma revealed hypointensity at precontrast and after 20 seconds. The SI then 
gradually increased with a centripetal fill-in enhancement and slight hyperintensity after 
120 seconds.
• HCC:
Seven of 16 HCCs exhibited no significant SI change at all time points after injection as 
compared with precontrast images (Figure 7). Six cases exhibited gradual enhancement 
with hypointensity at precontrast and after 20 seconds and iso- or slightly hyperintensity 
after 50 and 120 seconds. Two HCCs showed decreasing enhancement with isointensity 
after 20 seconds and hypointensity after 50 and 120 seconds.
• Metastasis:
In 2/4 metastases hypointensity at all time points were observed, the remaining 2 cases 
showed gradual enhancement with hypointensity at 20 seconds phase and isointensity at 
120 seconds phase. Two metastases showed ring enhancement outside the tumor margin 
at 120 seconds phase (Figure 8).
3.2.2.2 T1-weighted 3D-GRE Dynamic MR Image
• Adenoma:
All adenomas (n=3) presented with hyperintensity (Figure 9) with sharp margins with 
no change over time.
• FNH:
All FNHs (n=3) were almost isointense at all time points with only slight variations. 
Two  FNHs  had  an  internal  scar.  One  internal  scar  showed  gradually  increased 
enhancement after injection, the other remained hypointense (Figure 10). 
• Hemangioma:
In hemangioma two of 4 cases displayed nodular centripetal fill-in enhancement (Figure 
11),  the  remaining  two  cases  showed  homogenously  increasing  SI  without  nodular 
appearance.
• HCC:
Seven  of  9  HCCs  showed  no  significant  change  in  SI  at  all  time  points  with 
hypointensity in 4 cases, and isointensity, slight hyperintensity and mixed SI in each 
one. Two of 9 HCCs showed slight early enhancement and slight wash out. One HCC 
presented with ring enhancement outside the tumor margin after injection (Figure 12). 
• Metastasis:
In  9/10  metastases  no  significant  SI  change  was  observed  at  all  time  points  with 
hypointensity in 8 cases and mixed SI in one. One of 10 metastases showed isointensity 
after 20 seconds and hypointensity at the other 2 phases.
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Figure 1:
Artifacts due to motion in a case of hepatocellular carcinoma. 
1.1 Unenhanced-, and 1.2 Ferucarbotran-enhanced T2-weighted FSE images show poor 
image quality and poor lesion conspicuity.  1.3 Ferucarbotran-enhanced T2*-weighted 
GRE image shows good image quality with good lesion and vessel conspicuity. The 
HCC in left hepatic lobe (arrow) is not obvious in 1.1 and 1.2.
Figure 2:
Ghosting artifacts in a case of hemangioma. 
2.1 Unenhanced-,  2.2 Ferucarbotran-enhanced T2-weighted FSE images show a small 
high signal intensity hemangioma (arrow) in the left hepatic lobe.  2.3 Ferucarbotran-
enhanced T2*-weighted GRE image shows ghosting artifacts (arrow) arising from the 
aorta, which obscure the hemangioma in the left hepatic lobe.
Figure 3:
Hepatic adenoma in a patient with cardiomyopathy. 
3.1 Unenhanced T2-weighted FSE image shows a slightly hyperintense lesion (arrow) 
in  segment  VII.  3.2 Ferucarbotran-enhanced  T2-weighted  FSE  image  shows  an 
isointense lesion (arrow) with a central focus of high signal intensity. 3.3 Ferucarbotran-
enhanced T2*-weighted GRE image shows a lesion with low signal intensity a central 
focus of high signal intensity (arrow). This low signal intensity of the lesion was found 
typical for adenoma and can be used for the differentiation from FNH.
Figure 4:
Focal nodular hyperplasia. 
4.1 Unenhanced T2-weighted FSE image shows a focal iso-intense lesion (arrow) in 
segment  IV.  4.2 Ferucarbotran-enhanced  T2-weighted  FSE,  and  4.3 Ferucarbotran-
enhanced T2*-weighted GRE images show a slightly hyperintense focal lesion (arrow) 
in segment IV. The central scar is best seen as a hyperintense focus in 4.2.
Figure 5:
Hepatocellular carcinoma with mosaic pattern and peripheral capsule. 
5.1 Unenhanced-,  and  5.2 Ferucarbotran-enhanced T2-weighted FSE images  show a 
well-marginated round mass (arrow) with mosaic pattern and hypointense capsule in 
right  hepatic  lobe.  Some portion  of  the  mass  shows  signal  loss  after  ferucarbotran 
administration.  5.3 Ferucarbotran-enhanced  T2*-weighted  GRE  image  exhibits  a 
hyperintense  mass  (arrow)  with  no  definite  mosaic  pattern  nor  peripheral  capsule; 
however, the contrast between the lesion and the adjacent liver parenchyma is best seen 
in 5.3.
Figure 6:
Metastasis from a colorectal carcinoma with hyperintense rim outside the tumor. 
6.1 Unenhanced-,  6.2 Ferucarbotran-enhanced  T2-weighted  FSE,  and  6.3 
Ferucarbotran-enhanced  T2*-weighted  GRE  images  show  a  well-marginated 
hyperintense mass with hyperintense foci mimicking a central scar in the right hepatic 
lobe.  The  mass  lesion  is  depicted  with  increased  tumor-to-liver  contrast  after 
ferucarbotran administration. The hyperintense rim (arrows) outside the tumor is best 
seen in 6.3.
Figure 7:
Hepatocellular  carcinoma on ferucarbotran enhanced dynamic T1-weighted 2D-GRE 
images.
7.1 Pre-contrast;  7.2 20  seconds;  7.3 50  seconds;  and  7.4 120  seconds.  A well 
demarcated, round, slightly hyperintense mass (arrow) in the right hepatic lobe without 
significant signal intensity change at before and after contrast agent injection is seen.
Figure 8:
Metastasis on ferucarbotran enhanced dynamic T1-weighted 2D-GRE images.
8.1 Pre-contrast;  8.2 20  seconds;  8.3 50  seconds;  and  8.4 120  seconds.  A well 
demarcated and lobulated,  hypointense mass (arrow) in  right  hepatic  lobe with ring 
enhancement (8.3 and 8.4) outside the tumor margin can be delineated.
Figure 9:
Adenoma on ferucarbotran enhanced dynamic T1-weighted 3D-GRE VIBE images.
9.1 Pre-contrast;  9.2 20  seconds;  9.3 50  seconds;  and  9.4 120  seconds.  A well-
demarcated,  persistent  hyperintense  mass  (arrow)  adjacent  to  the  inferior  vena  cava 
before and after contrast agent injection can be noted.
Figure 10:
Focal nodular hyperplasia on ferucarbotran enhanced dynamic T1-weighted 3D-GRE 
VIBE images.
10.1 Pre-contrast;  10.2 20  seconds;  10.3 50  seconds;  and  10.4 120  seconds.  A 
conglomerated mass with central scar (arrows) in right hepatic lobe can be seen. After 
contrast agent injection the lesion shows isointensity to the liver parenchyma and the 
central scar shows gradual contrast enhancement.
Figure 11:
Hemangioma on ferucarbotran enhanced dynamic T1-weighted 3D-GRE VIBE images.
11.1 Pre-contrast;  11.2  20 seconds;  11.3 50 seconds; and  11.4 120 seconds.  A well-
demarcated mass (arrow) in left  hepatic lobe can be delineated. After contrast agent 
injection the lesion shows nodular, peripheral enhancement in the arterial phase and the 
typical fill-in enhancement over time.
Figure 12:
Hepatocelluar  carcinoma on  ferucarbotran  enhanced  dynamic  T1-weighted  3D-GRE 
VIBE images.
12.1 Pre-contrast;  12.2 20 seconds;  12.3 50 seconds; and  12.4 120 seconds. A well-
demarcated and slightly lobulated, hypointense lesion (arrow) in the right hepatic lobe 
can be seen. The lesion shows ring enhancement in outside the tumor margin.
5. DISCUSSION
The characterization of focal liver lesions as well as their detection is an important issue 
in liver imaging with major impact on further patient treatment and prognosis. The use 
of  extracellular  gadolinium chelate  contrast  agents  has  improved  the  capability  for 
lesion characterization in liver MR imaging based on tumor vascularity and diffusion of 
contrast agent into the extracellular space (6,49,55). Extracellular gadolinium chelates 
are primarily useful for tissue characterization of focal liver lesions with evaluation of 
the enhancement pattern using dynamic MR imaging. However, the detection rate is 
considered being not sufficiently high by many authors (15,18,20,37,47,59).
SPIO agents are primarily known to improve the detection of lesions with increased 
tumor-to-tissue contrast (1,11,28,36) and considered to be useful in preoperative liver 
MR imaging (1,4,10,46,48). In SPIO-enhanced MRI the differentiation between benign 
and malignant focal liver lesions is also possible on the basis of its cellular composition 
(RES cells in normal liver parenchyma and tumor) and function (2,3,36). Therefore, 
when the diagnostic efficacy of SPIO-enhanced liver MRI for the characterization of 
focal lesions is as sufficiently high as gadolinium chelates enhancement, it can be used 
as a useful diagnostic method with a cost-benefit and time-saving for the pretreatment 
or  preoperative  evaluation  and  follow-up  imaging  in  patients  with  malignant  liver 
lesions. 
5.1 Ferucarbotran-enhanced T2-/T2*- weighted Imaging Sequences
5.1.1 Characterization of Focal Liver Lesions 
SPIO agents are mainly used as negative contrast agents in the accumulation phase on 
T2/T2*-w  sequences  with  decreased  SI  of  normal  liver  parenchyma  and  nearly 
unchanged SI of  focal  lesions without  reticuloendothelial  cells.  Typically,  malignant 
liver  lesions  devoid  of  Kupffer’s  cells,  such  as  metastases  or  HCC  appear  as 
hyperintense lesions without significant SI loss against the dark background of the liver 
on  SPIO-enhanced  MRI.  In  contrast,  tumors  with  Kupffer’s  cells,  such  as  FNHs, 
adenomas and regenerative nodules or with a relevant blood pool, such as hemangiomas 
show a decrease in SI after SPIO administration. (4,11,36,55).
PSIL
The quantification  of  the  PSIL after  SPIO application  is  considered  to  be  different 
between  noncystic  benign  and  malignant  lesions  and  might  be  used  for  the 
differentiation  between  benign  and  malignant  lesions  in  SPIO-enhanced  liver  MR 
imaging (4,11,36,55). 
Vogl et al (55) reported a sensitivity of 88% and specificity of 89% with a threshold 
PSIL of 10% for distinguishing benign from malignant liver lesions on ferumoxide-
enhanced proton-density-w MR images. In the present study, we evaluated the PSIL 
with  a  standard  T2-w  FSE  sequence.  The  PSIL  of  noncystic  benign  lesions  was 
statistically  significantly  higher  than  that  of  malignant  lesions.  We  could  obtain  a 
sensitivity  of  97.8%  and  specificity  of  92.9%  with  a  threshold  PSIL of  25%  for 
distinguishing benign from malignant liver lesions. With a threshold PSIL of 20% or 
30% results were not dramatically worsened, so that there is still some safety buffer left. 
According to the results of previous and the present studies, therefore, we suggest that 
the differentiation between benign and malignant focal liver lesions is feasible with help 
of PSIL and should be performed in all cases, in which characterization of lesion is 
doubtful  on  visual  evaluation.  However,  as  a  prerequisite  for  performing  PSIL 
calculations the same T2-w FSE sequence has to be performed pre- and post SPIO-
application.
Characterization of each lesion type by means of PSIL is considered problematic in the 
literature, because the PSIL can vary with different imaging sequences and has shown 
overlap between the several  lesion types in the existing literature.  For example,  the 
mean PSIL have been reported as 8.8%, 41.0% ± 18.3 and 42% ± 9 in FNH, 32.4% ± 
6.9 and 74% in adenomas, and 11.2% ± 6.3, 21% ± 16 and 56% (range in 30 – 70%) in 
hemangiomas. Moreover, previous studies also reported an overlap between the PSIL of 
some benign lesions with that of well-differentiated HCC (4,11,14,55).
As shown in Graph 3 we also found variable and overlapping PSIL; however, mainly in 
malignant lesions. In our study the PSIL was not overlapped among adenomas, FNHs 
and hemangiomas, and the PSIL of adenomas was significantly higher than the PSIL of 
FNHs,  and  the  PSIL of  FNHs  was  significantly  higher  than  that  of  hemangiomas. 
Therefore, in contrast to previous studies, we also suggest that it may be possible to 
differentiate each benign lesion type by means of PSIL.
Differentiation between FNH and adenomas
Adenomas showed dark signal intensity on CE-T2*-w GRE images, which resulted in 
superior lesion conspicuity and lesion detectability in this sequence in contrast to CE-
T2-w FSE images. As previously reported by Vogl et al. (55), some adenomas showed 
central foci of high signal intensity within a mainly low signal intensity lesion on CE-
T2*-w GRE images. In previous reports (36,55) as well as in the present study, FNH 
showed never hypointensity as compared to surrounding liver parenchyma on SPIO-
enhanced MR images. Therefore, the finding of dark signal intensity lesion with central 
high signal intensity foci on CE-T2*-w GRE images can be useful in the diagnosis of 
adenoma in SPIO-enhanced MRI.
Diagnosis of Hemangioma
Hemangiomas showed variable SI from hypo- to highly hyperintensity with variable 
SNR and CNR on CE-T2-w FSE and CE-T2*-w GRE images.  Therefore, with both 
sequences  the  diagnosis  of  hemangioma  and  differentiation  from  other  benign  or 
malignant lesions may be difficult, and heavily T2-w FSE images as well as dynamic 
contrast-agent behavior is needed for the definite diagnosis of hemangioma. The reason 
for  the  variable  imaging  findings  after  SPIO  application  might  be  the  variable 
pathomorphology of hemangiomas. To our mind hemangiomas with few parenchyma 
(and few Kupffer cells) and large intravascular space show a different behavior than 
hemangiomas with more parenchyma and more Kupffer cells.
Differentiation between HCC and Metastases
Both  HCC  and  metastasis  are  presented  with  hyperintensity  with  no  statistically 
significant difference in the SNR and CNR between two lesion types on both NCE- and 
CE- imaging sequences, except for the CNR on CE-T2-w image. The PSIL were also 
not  statistically  significantly  different  between  two  lesion  types.  Therefore, 
differentiation between HCC and metastases may be impossible only with SI evaluation 
of  the  lesions.  It  has  been  pointed  out  in  various  studies  that  in  everyday  clinical 
practice  it  is  necessary  to  use  visual  criteria  of  morphologic  features  such  as  scar, 
capsule, hemorrhage, background cirrhosis in conjunction with quantitative criteria such 
as CNR and PSIL to achieve a correct diagnosis (6,36). 
Differentiation between Malignant and Coexisting Benign Lesions
Another difficulty in SPIO-enhanced MR imaging is differentiating malignant lesions 
with a cystic appearance from incidental coexisting benign lesions, such as hepatic cysts 
and  hemangiomas.  These  lesions  may appear  highly  hyperintense  against  the  black 
background of the liver, and small cysts or hemangiomas less than 10 mm may be a 
substantial source of false-positive finding on SPIO-enhanced MR imaging (4,5,24,35). 
At  present,  NCE-heavily  T2-w  SE  sequences  are  considered  helpful  for  the 
differentiation of hemangiomas and cysts from metastases (30,31,35). We also obtained 
the result that on NCE-T2-w FSE images the CNR of cysts and hemangiomas were 
statistically significantly higher than those of HCC or metastases. Moreover, we found 
that on CE-T2*-w GRE images the SNR and CNR of cysts were significantly lower than 
those of HCC or metastases.
5.1.2 Comparison of the Diagnostic Efficacy between T2-weighted FSE and T2*-w 
GRE Sequences in Ferucarbotran-enhanced Liver MRI
We evaluated  and  compared  the  efficacy  of  T2-w FSE and  T2*-w  GRE images  in 
ferucarbotran-enhanced  liver  MRI  by  means  of  qualitative  as  well  as  quantitative 
analysis, because the optimum imaging sequence has been one of the subjects of debate 
(1,24,40,51,53,58).. 
Overall Image Quality and Imaging Artifacts
Overall  image quality  was  superior  on  CE-T2*-w GRE images  over  CE-T2-w FSE 
images, which was mainly caused by the high number of examinations (48.5%) with 
motion artifacts on T2-w FSE images. Especially in patients with a large amount of 
ascites the motion artifacts in T2-w FSE sequences were so severe that they interfered 
with  image interpretation and obscured focal lesions. Artifacts arising on T2*-w GRE 
images  were  mainly  ghosting  artifacts.  However,  their  number  was  with  11.8% 
significantly lower than artifacts in T2-w FSE images. Moreover, the ghost artifacts did 
not affect image quality or image interpretation as much as motion artifacts in the T2-w 
images. Just in one case of hemangioma within our study group the lesion was obscured 
by a ghost artifact from the aorta on the CE-T2*-w GRE sequence. However, image 
degradation from metallic artifacts was more severe on T2*-w GRE images due to the 
sensitivity to susceptibility (1,5,12).
Lesion and Vessel Conspicuity
Kanematsu et al. (24) reported that on ferumoxide-enhanced T2*-w GRE images using 
150/10 (TR msec/TE msec) the CNR of malignant lesions was lower than on T2-w FSE 
images and was almost the same in nonsolid benign lesions. Therefore, they suggested 
that the differentiation between nonsolid benign and solid malignant lesions might be 
difficult on ferumoxide-enhanced T2*-w GRE images.
In our study, however, lesion conspicuity of malignant lesions was superior with a high 
CNR on CE-T2*-w GRE images  with  117/10/30° (TR msec/TE msec/flip  angle)  in 
contrast to CE- T2-w FSE images. Especially in HCC, the CNR was significantly higher 
on CE-T2*-w GRE images than on CE- T2-w FSE images, which might be the main 
reason for the superior lesion conspicuity and lesion detectability. In hepatic cysts the 
lower lesion conspicuity with only slight hyperintensity on CE-T2*-w GRE images was 
helpful to differentiate them from markedly hyperintense malignant lesions. Therefore, 
we  suggest  that  T2*-w  GRE  sequence  are  especially  helpful  for  lesion  detection; 
however  they  can  be  also  helpful  for  the  differentiation  between  hepatic  cysts  and 
malignant lesions. 
Adenomas showed dark signal intensity on CE-T2*-w GRE images, which resulted in 
superior lesion conspicuity and lesion detectability in this sequence in contrast to CE-
T2-w FSE images.
It has been reported that on T2*-w GRE images vessel are depicted hyperintense with 
high vessel-to-liver CNR, whereas on T2-w SE or FSE uneven signal intensity is noted. 
Therefore,  T2*-w GRE are considered to be more useful  for preoperative segmental 
analysis  of  focal  liver  lesions  than  T2-w  SE  or  FSE  images  (53).  We  could  also 
demonstrate superior vessel conspicuity on T2*-w GRE images.
Evaluation of Morphological Feature and Secondary Findings of the Tumor
We investigated the efficacy of T2-w FSE and T2*-w GRE sequences for the evaluation 
of morphological features of focal lesions, such as mosaic pattern, capsule, scar and 
portal  vein  thrombosis.  There  was  no  significant  difference  in  the  efficacy  for  the 
evaluation of these morphological features between the two imaging sequences. Only in 
the evaluation of mosaic pattern a tendency of superiority on T2-w FSE images was 
noted. The hyperintense ring at the rim of a malignant tumor might be a helpful finding 
for characterization of focal liver lesions in SPIO-enhanced MR imaging (19,32,41). In 
our  study this  finding  was  noted  easier  on  CE-T2*-w GRE than  on  CE-T2-w FSE 
sequences without statistical significance.
5.2 Ferucarbotran-enhanced T1-weighted Dynamic MR Imaging
SPIO agents can also be used as positive contrast agents due to T1 shortening at low 
concentrations. Several studies could show an improved characterization of focal liver 
lesions on T1-w images in the accumulation phase (13,35,44).
Ferucarbotran  is  a  bolus-injectable  SPIO  agent  without  cardiovascular  side  effect 
(1,17,56).  The  characterization  of  focal  liver  lesions  by  means  of  ferucarbotran-
enhanced dynamic MR imaging has been reported and characteristic findings have been 
demonstrated in a limited number of cases (34,39,41,54).
We performed ferucarbotran-enhanced T1-w dynamic MR imaging using two different 
GRE sequences (2D-GRE and 3D-GRE VIBE) and evaluated the change in SNR and 
CNR  of  normal  liver  tissue,  vascular  structures  and  focal  liver  lesions  on  each 
sequences. We could find out differences in change of SNR and CNR and enhancement 
patterns of the liver, vascular structures and focal lesions between the two sequences.
5.2.1 Evaluation of Enhancement Pattern in Liver and Vascular Structures 
All vascular structures (aorta, portal vein and IVC) showed early increase in SNR at 20 
seconds after injection on both sequences, however the increase was more pronounced 
in the 3D-GRE images.  The  SNR of  the liver  showed also an early  increase at  20 
seconds after injection. The resulting CNR between all vascular structures and the liver 
parenchyma showed negative values at 20 and 50 seconds after injection for 2D-GRE 
images, which means that vascular structures were hypointense in comparison to the 
liver parenchyma and could mimic small focal liver lesions. In contrast, on 3D-GRE 
VIBE images  the  vascular  structures  showed positive  CNR at  all  time  points  after 
injection.  In addition,  the change in SNR and CNR of the aorta on 3D-GRE VIBE 
images was similar to that known from gadolinium chelates with an early rapid increase 
followed by a slight decrease with persistent positive enhancement (27). These findings 
suggest that the 3D-GRE VIBE sequence is more useful in comparison to a 2D-GRE 
sequence for the evaluation of the vascular structures and for the differentiation between 
vascular structure and small focal lesion.
5.2.2 Evaluation of Enhancement Pattern in Focal Liver Lesions 
Tumor Vascularity
Vogl et al. (54) reported a rapid decrease in SI of hypervascular tumors such as FNH, 
hemangioma and HCC between 22 and 44 seconds after injection of ferucarbotran on 
T2-w GRE sequence. These lesion types showed a rapid increase in SI on T1-w GRE 
sequences, whereas metastasis did not demonstrate significant change of SI on T1-w 
GRE and T2-w GRE sequences  (34,39,41,54).  Therefore  the  authors  suggested  that 
dynamic imaging of the perfusion phase with SPIO might be used to evaluate tumor 
vascularity.
With regard to lesion vascularity our study showed different findings as compared to 
previous  reports.  We  could  also  observe  differences  in  the  enhancement  pattern  of 
different liver lesions between 2D-GRE and 3D-GRE VIBE sequences.
Both HCC and metastasis showed similar changes of SNR on 2D-GRE sequences with 
an  increase  at  20  seconds,  which  was  not  noticed  on  3D-GRE  VIBE  dynamic 
sequences.  A persistent  negative  mean  CNR was  seen  in  both  lesions  and  in  both 
sequences at all time points. The expected strong enhancement of HCC with positive 
contrast at least 20 seconds after injection could not be identified, suggesting that the 
evaluation of tumor vascularity in malignant liver lesions for differentiation between 
hypervascular  HCC and hypovascular  metastases  with  ferucarbotran-enhanced T1-w 
dynamic GRE imaging, either with 2D or 3D technique, is difficult or impossible. 
With regard to benign hypervascularized liver lesions two different groups have to be 
considered, on the one hand hemagioma on the other adenoma and FNH....................... 
In our study all  hemangiomas (n=6) showed centripetal  fill-in enhancement with an 
early increase in SI at 20 and/or 50 seconds. Moreover, two hemangiomas showed the 
typical nodular enhancement in 3D-GRE VIBE images. These results are comparable to 
previous  studies  (34,39,41)............................................................................................... 
In  FNH  and  adenoma,  however,  hypervascularity  could  not  be  demonstrated  with 
ferucarbotran-enhanced dynamic MRI in our  series.  All  FNHs showed more or  less 
isointensity with a CNR around zero at all time points. All adenomas showed no early 
increase in SNR and CNR and showed relatively consistent values after ferucarbotran-
enhanced T1-w images in contrast to gadolinium-enhanced dynamic MRI.
Therefore  we  suggest  that  ferucarbotran-enhanced  dynamic  T1-w  GRE MRI  has  a 
different  enhancement  mechanism  and  is  not  giving  the  same  information  for  the 
evaluation of tumor vascularity as gadolinium chelates.
Characteristic Findings in Benign Liver Lesions
All hemangiomas (n=6) showed centripetal fill-in enhancement pattern on both 2D and 
3D techniques. Moreover, two hemangiomas showed the typical nodular enhancement 
in  3D-GRE  VIBE  images................................................................................................ 
We could also observe specific findings in a limited number of FNH (n=3) and adenoma 
(n=3) at 3D-GRE VIBE images. All FNHs showed more or less isointensity at all time 
points. In 2/3 cases an internal scar could be detected on dynamic images with gradual 
enhancement comparable with gadolinium-enhanced dynamic MRI.
Adenoma showed  the  highest  SNR and  CNR at  precontrast  and  contrast  enhanced 
dynamic images in our study. The high SI on precontrast T1-w images can be explained 
by a high glycogen content of the cells (2,3). Consistent high SI without significant 
change  on  ferucarbotran-enhanced  T1-w GRE dynamic  imaging  may  be  used  as  a 
specific finding in the diagnosis of adenoma in comparison to malignant lesions and 
FNHs, which presented hypointense respectively isointense in our series at  all post-
contrast imaging time points.
Cysts showed the lowest SNR and CNR values without significant enhancement, which 
is also a typical finding on gadolinium-enhanced dynamic MRI.
Differentiation between Benign and Malignant Focal Lesions
One possibility for the differentiation of benign from malignant lesions, especially in 
metastases, is presence of ring enhancement in malignant lesions adjacent to the tumor 
on  SPIO-enhanced  static  and  dynamic  T1-w  GRE  MRI,  which  showed  ring 
enhancement of liver metastases significantly more frequently (80%) than T2*-w GRE 
(36%) (19,32,34,39,41). In our study a ring enhancement pattern was demonstrated in 
only two of four metastases on 2D-GRE images and none of 10 metastases on 3D-GRE 
VIBE images. The discrepancy of the rates between previous reports and our study may 
be  explained  with  the  different  time  points  for  the  dynamic  studies.  The  ring 
enhancement pattern reported in the literature was demonstrated mainly at late perfusion 
(> 120 sec) and accumulation phases (19,32,39). However, we performed early dynamic 
studies only up to 120 seconds after injection. This difference might be the explanation 
for a less frequently demonstrated ring enhancement pattern in metastases in our study.
On 3D-GRE VIBE dynamic sequences benign solid  lesions  including hemangiomas 
showed  isointensity  or  slight  hyperintensity  at  all  time  points  whereas  most  of 
malignant  lesions  showed  marked  hypointensity.  This  finding  can  be  used  for  the 
differentiation  between  benign  and  malignant  lesions  in  the  early  dynamic  phase. 
Further  delayed  images  (over  120  seconds  after  injection)  may  be  helpful  to 
differentiate malignant lesions from slowly and gradually enhancing hemangioma. 
5.2.3  Advantages  of  3D-GRE  VIBE  sequences  over  2D-GRE  in  ferucarbotran-
enhanced dynamic T1-w liver MR Imaging
3D-GRE VIBE may be more useful for the evaluation of the vascular structure and for 
the differentiation between vascular structures and small focal liver lesion 50 seconds 
after injection. Moreover, with 3D-GRE VIBE the differentiation between benign and 
malignant lesions and specific diagnosis of benign lesions (cyst, adenoma, hemangioma, 
FNH) may be possible.
In addition, 3D imaging has potential advantages over 2D imaging. In comparison with 
traditional 2D GRE sequences, 3D GRE VIBE sequences have the capacity to provide 
thinner sections, no gaps, fat saturation, higher SNR, and comparable image contrast in 
the same breath-hold time frame. Therefore, with 3D GRE VIBE imaging, the pitfalls of 
intersection  gaps  and  partial  volume  artifacts  associated  with  2D  imaging  can  be 
avoided,  and fat  saturation improves CNR and reduces  the potential  degradation of 
image  quality  resulting  from motion-related  artifacts.  Other  advantages  include  the 
opportunity  to  reformat  images  in  any  plane  without  loss  of  image resolution.  The 
sequence  also  differs  by  including  a  decreased  flip  angle  to  improve  contrast  in 
abdominal imaging (27,42). 
5.3 Study limitation
A number of limitations are present in this study.
First, the exact comparison between T2-w FSE and T2*-w GRE sequences with regard 
to the ferucarbotran effect and the PSIL was impossible, because our routine protocol 
for ferucarbotran-enhanced liver MRI contained no NCE-T2*-w GRE sequence, which 
is considered unnecessary precontrast due to the low soft tissue contrast. 
Second, pathologic correlation was not available in every case in our study and that an 
exact  lesion  tracking  was  not  possible.  Therefore  the  results  of  lesion  detection  in 
comparison of T2-w FSE and T2*-w GRE sequences might have a systemic mistake.
At  last,  the  number  of  patients,  especially  with  benign  liver  lesions  was  small. 
Moreover, the selection of only one lesion per patient even in patients with multiple 
lesions can be criticized. However, this was mainly done since in our experience the 
enhancement pattern of the same lesion type within the same patient was constant. By 
evaluation of more than one lesion per patient the number of evaluated lesions would 
have been far higher suggesting a higher statistical confidence than would be realistic.
5.4 Conclusion
Solid benign lesions show SPIO uptake with a significant signal loss in a T2-w FSE 
sequence in contrast to malignant lesions. When a threshold of 25% is used, PSIL is an 
accurate tool for the characterization of benign and malignant lesions. For the detection 
of malignant lesions, the additional use of a CE-T2*-w GRE sequence is helpful due to 
the significantly higher CNR, a superior lesion conspicuity and better image quality in 
comparison to a CE-T2-w FSE sequence.
Early dynamic ferucarbotran-enhanced MRI with T1-w sequences is feasible. However, 
neither  T1-w  3D-GRE  VIBE  nor  T1-w  2D-GRE  sequences  did  provide  the  same 
information known from dynamic gadolinium-enhanced MRI. For the evaluation of the 
liver  vasculature  the  3D-GRE  VIBE  sequence  exhibits  advantages,  since  it  better 
resembles  the  vascular  enhancement  pattern  known from gadolinium.  The observed 
enhancement pattern of focal liver lesions in ferucarbotran-enhanced 3D-GRE VIBE 
seemed  more  specific  than  in  2D-GRE  imaging,  so  that  differentiation  between 
malignant and benign lesions might be possible in the 3D-GRE VIBE sequence.
In clinical implication of ferucarbotran-enhanced liver MRI, the differentiation between 
benign and malignant lesions can be possible with PSIL at T2-w FSE imaging sequence. 
The differentiation between the benign lesions (adenoma, FNH and hemangioma) may 
be  possible  with  the  evaluation  of  enhancement  pattern  at  dynamic  T1-w  GRE 
sequences.  Unless  using  the  visual  criteria  of  morphologic  features  such  as  scar, 
capsule,  hemorrhage,  background  cirrhosis,  neither  the  PSIL at  T2-w FSE  nor  the 
enhancement  pattern at  dynamic  T1-w GRE sequences  can  help to  differentiate  the 
malignant lesions (HCC, metastasis and CCC). 
6. SUMMARY
Superparamagnetic  iron  oxides  (SPIO)-enhanced  liver  MRI  is  considered  a  useful 
preoperative diagnostic method with high sensitivity and specificity for the detection of 
focal liver lesions. With SPIO-enhanced MRI the differentiation between benign and 
malignant focal liver lesions is also possible on the basis of its cellular composition 
(RES cells in normal liver parenchyma and tumor) and function. 
In earlier clinical trials the effects of SPIO particles were evaluated almost exclusively 
at T2-weighted (w) fast-spin echo (FSE) and T2*-w gradient echo (GRE) sequences 
because of main T2- or T2*- shortening effect of the SPIO particles. 
Ferucarbotran  is  a  bolus-injectable  SPIO  agent  without  cardiovascular  side  effect. 
Dynamic T1-w perfusion MRI following bolus injection of ferucarbotran might provide 
information about the vascularity of solid liver lesions. The characterization of focal 
liver  lesions  by  means  of  ferucarbotran-enhanced  dynamic  MR  imaging  has  been 
reported and characteristic findings have been demonstrated on a limited number of 
cases.
The first purpose of our study was to evaluate the efficacy of SPIO agent ferucarbotran 
in T2-w FSE and T2*-w GRE sequences for the characterization of focal liver lesions. 
The second aim was to evaluate the enhancement  pattern of ferucarbotran-enhanced 
early  dynamic  MR  imaging  with  2D-GRE  and  3D-GRE  VIBE  sequences  for  the 
characterization of focal liver lesions.
On a 1.5 T MR-system noncontrast-enhanced (NCE) and contrast-enhanced (CE) T2-w 
FSE images  and  CE- T2*-w  GRE images  10  minutes  after  i.v.-injection  of  1.4  ml 
ferucarbotran were obtained in 68 patients.
On a 1.5 T MR system T1-w dynamic images were obtained with 2D-GRE sequences in 
23 patients and 3D-GRE VIBE sequence in 37 patients. 
The final diagnoses of the 68 patients, in whom T2-w FSE/ T2*-w GRE sequences were 
performed,  included  hepatocellular  carcinomas  (HCC,  n=29),  metastases  (n=15), 
cholangiocellular carcinomas (CCC, n=2), hemangiomas (n=6), adenomas (n=5), focal 
nodular hyperplasias (FNH, n=3) and cysts (n=8). 
The final diagnoses of the 60 patients, in whom T1-w early dynamic MR imaging was 
performed, included HCC (n=25), metastasis (n=14), CCC (n=2), hemangiomas (n=6), 
adenomas (n=3),  FNH (n=3) and cysts  (n=7).................................................................. 
On T2-w FSE/ T2*-w GRE images the signal-to-noise ratio (SNR) and contrast-to-noise 
ratio  (CNR)  based  on  signal  intensity  measurements  in  focal  lesions  and  liver 
parenchyma were  calculated  for  all  sequences.  The  percentage  signal  intensity  loss 
(PSIL) of focal lesions from NCE- to CE- was calculated for the T2-w FSE sequence. 
Qualitative analysis was performed for the image quality and lesion conspicuity at CE-
T2-w FSE and CE-T2*-w GRE sequences. 
In  T1-w early  dynamic MR imaging SI  measurements  in the liver  parenchyma,  the 
hepatic vasculature and in focal lesions were performed precontrast and 20, 50 and 120 
seconds after bolus-injection of ferucarbotran to calculate the SNR and CNR.
The mean SNR of solid benign lesions showed a decrease from 34.1 to 21.0 (p<0.05). In 
malignant lesions, the mean SNR showed only a minor decrease from 33.3 to 32.5. The 
mean CNR of  the malignant  lesions was the  highest  in  the  CE-T2*-w sequence  as 
compared to the post- and the pre-contrast T2-w FSE sequence (29.9 vs. 22.7 (p<0.01) 
vs. 12.8 SI (p<0.01)). With a threshold PSIL of 25 %, the sensitivity and specificity for 
the  characterization  of  malignant  lesions  was  97.8%  respectively  92.9%  in 
ferucarbotran-enhanced T2-w FSE. There was no overlap between the PSIL of adenoma 
and  FNH.  CE-T2*-w  GRE  images  showed  a  superior  image  quality  and  lesion 
conspicuity (p < .05) as compared to the CE-T2-w FSE sequence. 
With early dynamic ferucarbotran-enhanced MRI hypervascularity could not be shown 
in  typically  hypervascularizied  lesions  such  as  HCCs,  adenomas  or  FNHs.  In 
hemangiomas  fill-in  enhancement  could  be  observed  in  all  cases.  In  the  3D-GRE 
sequence  mean CNR for  solid  benign  lesions  was  around zero  (FNH) or  markedly 
positive (adenoma), whereas mean CNR for malignant lesions was negative at all time 
points.
In conclusion, solid benign lesions show SPIO uptake with a significant signal loss in a 
T2-w FSE sequence in contrast to malignant lesions. When a threshold of 25% is used, 
PSIL is an accurate tool for the characterization of benign and malignant lesions. For the 
detection of malignant lesions, the add-on of a CE-T2*-w GRE sequence is helpful due 
to the significant higher CNR, a superior lesion conspicuity and better image quality in 
comparison to the CE-T2-w FSE sequence. 
With  3D-GRE  sequences  after  bolus-injection  of  ferucarbotran  the  differentiation 
between benign and malignant lesions and the characterization of benign lesions may be 
possible. Both 2D- and 3D- GRE techniques do not provide the same information about 
liver lesion vascularity as gadolinium-enhanced MRI.
Zusammenfassung
Die  Superparamagnetic  Iron  Oxides  (SPIO)-verstärkte  MRT  der  Leber  wird  als 
sinnvolle  präoperative  diagnostische  Methode  mit  einer  hohen  Sensitivität  und 
Spezifität  für  die  Detektion  von  fokalen  Leberläsionen  angewendet.  Mit  der  SPIO-
verstärkten MRT ist aber prinzipiell auch eine Differenzierung zwischen benignen und 
malignen  fokalen  Leberläsionen  möglich  auf  der  Basis  ihrer  zellulären 
Zusammensetzung  und  Funktion  (RES-Zellen  in  normalem  Lebergewebe  und  in 
benignen Tumoren, keine RES-Zellen in malignen Tumoren).
In früheren Studien wurden die Effekte von SPIO-Kontrastmitteln fast ausschließlich 
auf die Detektion von Läsionen sowie die Effekte in T2-gewichteten (w) Fast-Spin Echo 
(FSE)  und  T2*-w  Gradienten  Echo  (GRE)  Sequenzen  beschränkt,  da  SPIO 
hauptsächlich die T2 / T2* - Zeiten verkürzen.
Ferucarbotran  ist  ein  relativ  neu  zugelassenes  SPIO-Kontrastmittel,  welches  als 
intravenöser  Bolus  appliziert  werden  kann  und  sich  durch  eine  geringe 
Nebenwirkungsrate  vor  allem  im  kardiovaskulären  Bereich  auszeichnet.  Eine 
dynamische  T1-w  Perfusionsmessung  nach  der  Bolusapplikation  von  Ferucarbotran 
könnte Informationen über die Vaskularisation solider Tumore in der Leber liefern. Die 
Möglichkeit  der  Charakterisierung  von  fokalen  Leberläsionen  mit  Hilfe  der 
dynamischen Ferucarbotran-verstärkten MRT wurde bereits in der Literatur angedeutet 
und typische Befunde konnten an einer begrenzten Anzahl  von Fällen  für einzelne 
fokale Leberläsionen gezeigt werden. 
Das erste Ziel dieser Arbeit war die Evaluierung der diagnostischen Effizienz des SPIO 
Kontrastmittel  Ferucarbotran  in  T2-w  FSE  and  T2*-w  GRE  Sequenzen  zur 
Charakterisierung  von  fokalen  Leberläsionen.  Das  zweite  Ziel  war  es  typische 
Anreicherungsmuster fokaler Leberläsionen in der dynamischen T1-w MRT mit  2D-
GRE and 3D-GRE VIBE Sequenzen zu beschreiben.
An einem 1.5 Tesla MRT-System wurden native und kontrastverstärkte T2-w FSE and 
T2*-w GRE Sequenzen 10 Minuten nach Bolusinjektion von 1.4 ml Ferucarbotran bei 
68 Patienten durchgeführt. An einem 1.5 Tesla MRT-System wurden T1-w dynamische 
Bilder bei 23 Patienten mit einer 2D-GRE Sequenz und bei 37 Patienten mit einer 3D-
GRE-VIBE Sequenz akquiriert.
Die endgültige Diagnose der 68 Patienten, bei denen T2-w FSE/ T2*-w GRE Sequenzen 
durchgeführt  wurden war Hepatozelluläres Karzinom (HCC, n=29),  Lebermetastasen 
(n=15),  Cholangiozelluläres  Karzinom  (CCC,  n=2),  Hämangiom  (n=6), 
Leberzelladenom (n=5), Fokal Noduläre Hyperplasie (FNH, n=3) und Zysten (n=8). Die 
endgültige Diagnose der 60 Patienten, bei denen eine T1-w dynamische Ferucarbotran-
verstärkte MRT durchgeführt wurde war HCC (n=25), Lebermetastasen (n=14), CCC 
(n=2), Hämangiom (n=6), Leberzelladenom (n=3), FNH (n=3) and Zysten (n=7). In den 
T2-w FSE und T2*-w GRE Bildern wurde das Signal-zu-Rausch-Verhältnis (SNR) und 
das  Kontrast-zu-Rausch-Verhältnis  basierend  auf  Signalintensitätsmessungen  in  den 
fokalen  Läsionen  und  dem  Leberparenchym  durchgeführt.  Der  prozentuale 
Signalverlust  (PSIL)  der  verschiedenen  fokalen  Läsionen  von  der  nativen  zur 
kontrastverstärkten T2-w FSE –Sequenz wurde errechnet. Eine qualitative Auswertung 
der  Bildqualität  sowie  der  Abgrenzbarkeit  der  Läsionen  im  Vergleich  zwischen 
kontrastverstärkten T2-w FSE und kontrastverstärkten T2*-w GRE Bildern erfolgte. In 
den  T1-w  dynamischen  Bildern  wurden  Signalintensitätsmessungen  im 
Leberparenchym, den Lebergefäßen und in fokalen Leberläsionen vorgenommen um 
SNR und CNR zu errechnen.
Das mittlere SNR von soliden benignen Läsionen zeigte einen Abfall in der T2-w FSE 
Sequenz  von  34.1  vor  auf  21.0  (p<0,05)  nach  Kontrastmittelgabe;  maligne 
Leberläsionen  zeigten  nur  einen  geringen  Signalverlust  von  33.3  auf  32.5  (nicht 
signifikant).  Das  mittlere  CNR  der  malignen  Läsionen  war  am  höchsten  in  der 
kontrastverstärkten T2*-w Sequenz vergleichen mit der nativen- und kontrastverstärkten 
T2-w FSE Sequenz (29.9 vs. 22.7 (p<0.01) vs. 12.8 SI (p<0.01)). Bei einem Grenzwert 
von 25 % Signalverlust (PSIL) in der T2-w FSE Sequenz konnte eine Sensitivität und 
Spezifität von 97.8% beziehungsweise 92.9% mit der Ferucarbotran-verstärkten T2-w 
MRT erreicht werden. Der Signalverlust (PSIL) von Adenomen und FNH zeigte keine 
Überschneidungen. Kontrastverstärkte T2*-w GRE Bilder zeichneten sich durch eine 
überlegene Bildqualität und Abgrenzbarkeit von Läsionen (p < .05) im Vergleich zur 
kontrastverstärkten  T2-w  FSE  Sequenz  aus.  In  der  dynamischen  Ferucarbotran-
verstärkten  T1-w  MRT  konnte  eine  Hypervaskularisation  in  den  typischerweise 
hypervaskularisierten Läsionen wie HCC, Adenom oder FNH nicht gezeigt werden. In 
Hämangiomen hingegen war ein frühes Enhancement in allen Fällen abzugrenzen. In 
der T1-w 3D-GRE Sequenz lag das mittlere CNR der soliden benignen Läsionen bei 
etwa null  (FNH) oder  war  sogar  positiv  (Adenom),  während das  mittlere  CNR der 
malignen Läsionen im negativen Bereich zu allen Zeitpunkten lag.
Zusammenfassend konnte gezeigt  werden,  dass  solide  benigne Läsionen eine  SPIO-
Speicherung zeigen, welche einen signifikanten Signalabfall in den Läsionen in T2-w 
Bildern  hervorruft.  Mit  einem  Grenzwert  von  25%  Signalverlust  (PSIL)  kann  eine 
sichere  Unterscheidung  von  benignen  und  malignen  Läsionen  erfolgen.  Für  die 
Detektion  von  Läsionen  ist  eine  zusätzliche  T2*-w  Sequenz  hilfreich  wegen  des 
stärkeren  Läsion-zu-Leber-Kontrastes  (CNR),  einer  verbesserten  subjektiven 
Abgrenzbarkeit der Läsionen und der besseren Bildqualität. Mit der dynamischen T1-w 
MRT  mit  einer  3D-GRE  Sequenz  nach  Bolusinjektion  von  Ferucarbotran  können 
möglicherweise  Aspekte  zur  Charakterisierung  von  malignen  versus  benignen 
Leberläsionen  gewonnen  werden.  Allerdings  liefert  die  T1-w  dynamische  MRT 
offensichtlich weder mit 2D- noch mit 3D-GRE Sequenzen die gleiche Information über 
die Vaskularisation von Leberläsionen wie die Gadolinium-verstärkte MRT, da die von 
den  extrazellulären  Kontrastmitteln  bekannten  Anreicherungsphänomene  in 
hypervaskularisierten  Leberläsionen  mit  der  dynamischen  Ferucarbotran-verstärkten 
MRT nicht nachvollzogen werden konnten......................................................................... 
Für die Praxis bedeutet dies, dass der Schwerpunkt der Ferucarbotran-verstärkten MRT 
Untersuchung  weiterhin  bei  den  T2-w  und  T2*-w  Sequenzen  liegt,  um  die  in  der 
Literatur  berichteten  hohen  Detektionsraten  und  die  von  uns  untersuchten 
Möglichkeiten  zur Charakterisierung auszunutzen. Die während der Bolusapplikation 
durchgeführte T1-w dynamische Bildgebung kann in limitierten Fällen wie z.B. Häma-
ngiomen  differentialdiagnostische  Hilfestellungen  liefern,  kann  aber  die  Information 
einer dynamischen Untersuchung mit extrazellulären Kontrastmitteln nicht ersetzten.
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